Sandoz Can't Escape Teva's Copaxone Patent Suit

Law360, New York (September 8, 2010, 5:53 PM EDT) -- Sandoz Inc. and Momenta Pharmaceuticals Inc. have lost their bid to upend Teva Pharmaceuticals USA Inc.'s suit accusing the generic-drug makers of infringing several patents in their effort to manufacture a copycat version of multiple sclerosis drug Copaxone.

Judge Barbara S. Jones of the U.S. District Court for the Southern District of New York on Tuesday denied the defendants' motion for summary judgment, ruling that Sandoz and Momenta had failed to adequately prove that the asserted patents were invalid due to indefiniteness.

In a Dec. 23...
To view the full article, register now.